Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phospholipids accelerate factor IX activation by surface bound factor XIa.

C Mannhalter, S Schiffman, E Deutsch

    British Journal of Haematology
    |February 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of Escherichia coli K12 and O18:K1 on human platelets: Differential effects on platelet activation, RNAs and proteins.

    Scientific reports·2018
    Same author

    Hamostaseologie·2018
    Same author

    High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB).

    Haemophilia : the official journal of the World Federation of Hemophilia·2018
    Same author

    Platelet-borne complement proteins and their role in platelet-bacteria interactions.

    Journal of thrombosis and haemostasis : JTH·2016
    Same author

    Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

    Leukemia·2016
    Same author

    Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.

    Haemophilia : the official journal of the World Federation of Hemophilia·2015
    Same journal

    Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

    British journal of haematology·2026
    Same journal

    Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes.

    British journal of haematology·2026
    Same journal

    Author response to Zhang and Chen.

    British journal of haematology·2026
    Same journal

    Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

    British journal of haematology·2026
    Same journal

    Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

    British journal of haematology·2026
    Same journal

    Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

    British journal of haematology·2026
    See all related articles

    Phospholipids, like cephalin, significantly accelerate blood coagulation factor IX activation by factor XIa. This suggests phospholipids play a crucial role earlier in the coagulation cascade than previously understood.

    Area of Science:

    • Biochemistry
    • Hematology
    • Cell Biology

    Background:

    • Factor IX activation is a critical step in the intrinsic pathway of blood coagulation.
    • Factor XIa is known to activate factor IX, but the precise role of cofactors has been under investigation.
    • Previous understanding suggested phospholipids were involved later in the coagulation cascade.

    Purpose of the Study:

    • To investigate the effect of cephalin (a phospholipid) on the activation of bovine factor IX by factor XIa.
    • To determine the optimal concentration and dilution of cephalin for accelerating factor IX activation.
    • To elucidate the role of phospholipids in the early stages of blood coagulation.

    Main Methods:

    • Activation of factor IX using purified human factors XII, high molecular weight kininogen (HMWK), and XI, or factor IX deficient plasma.

    Related Experiment Videos

  • Incubation of factor IX with varying dilutions of human brain cephalin (1:5 to 1:500).
  • Assay of factor IX activation and protein cleavage rates in the presence and absence of cephalin.

    • Main Results:

    • Cephalin significantly accelerated factor IX activation by factor XIa in a concentration-dependent manner.
    • Optimal acceleration was observed with cephalin dilutions from 1:5 to 1:30 for concentrated factor IX, and 1:30 to 1:250 for dilute factor IX.
    • Phospholipid presence led to increased factor IX cleavage and faster generation of factor IXa activity.

    Conclusions:

    • Phospholipids, specifically cephalin, actively participate in blood coagulation by accelerating factor IX activation.
    • The findings indicate that phospholipids are involved at an earlier stage in the coagulation cascade than previously recognized.
    • This study highlights the essential role of phospholipids in facilitating the enzymatic reactions of blood coagulation.